Literature DB >> 16919046

Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin.

A M Galán1, W L van Heerde, G Escolar, A Ordinas, J Sixma, P G de Groot.   

Abstract

The role of phospholipid platelet membrane and tissue factor in thrombin generation and thrombus formation is accepted. In the present study we have explored antithrombotic action of strategies aimed to block exposure of negatively charged phospholipids and we compared effects with those obtained through tissue factor or a direct thrombin inhibition. Type III collagen was exposed to flowing blood (5 min, 300 s(-1)). Effects of inhibition of platelet deposition by annexin A5 (ANXA5), hirudin (HIR) or by an antibody against tissue factor (TF) were evaluated. Prothrombin fragment F1 + 2 (F1 + 2) was monitored. Pre-incubation of whole blood with HIR or ANXA5 resulted in a statistically significant reduction of platelet deposition (12.2 +/- 0.6% in control experiments vs. 8.3 +/- 0.4% and 8.5 +/- 0.5%, respectively, P < 0.05). A similar decrease was found when blood was incubated with an antibody against TF. Furthermore, ANXA5 and HIR inhibited the recruitment of platelets into forming aggregates. The height of platelet aggregates generated was decreased in the presence of HIR or ANXA5, but only incubation with both inhibitors reached levels of statistical significance. The presence of ANXA5 or HIR decreased levels of F1 + 2 suggesting a reduced activation of the coagulation system. In our experimental studies, the inhibitory potential of ANXA5 on platelet-thrombus formation was as effective as that of a direct thrombin inhibitor, as HIR, or an antibody against TF. Negatively charged phospholipids exposed on activated platelets potentiate the formation of platelet aggregates on a collagen surface and further suggest that inhibition of platelet procoagulant activity might be a specific target for antithrombotic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919046     DOI: 10.1111/j.1365-2362.2006.01698.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.

Authors:  Irene Lopez-Vilchez; Ulla Hedner; Carmen Altisent; Maribel Diaz-Ricart; Gines Escolar; Ana M Galan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

2.  Annexin A5 increases survival in murine sepsis model by inhibiting HMGB1-mediated pro-inflammation and coagulation.

Authors:  Jung Hwa Park; Jong-Hwa Jang; Eun Jung Choi; Young Seob Kim; Eun Ji Lee; In Duk Jung; Hee Dong Han; T-C Wu; Chien-Fu Hung; Tae Heung Kang; Yeong-Min Park
Journal:  Mol Med       Date:  2016-07-06       Impact factor: 6.354

Review 3.  Proteomic analysis in cardiovascular research.

Authors:  Teiji Oda; Ken-ichi Matsumoto
Journal:  Surg Today       Date:  2015-04-19       Impact factor: 2.549

4.  Diannexin Can Ameliorate Acute Respiratory Distress Syndrome in Rats by Promoting Heme Oxygenase-1 Expression.

Authors:  Ying-Nan Ju; Qi-Hang Tai; Guang-Xiao Xu; Xiao-Qing Zhao; Hai-Bin Sun; Wei Gao
Journal:  Mediators Inflamm       Date:  2021-04-09       Impact factor: 4.711

5.  Relationship between the Soluble F11 Receptor and Annexin A5 in African Americans Patients with Type-2 Diabetes Mellitus.

Authors:  Ajibola Adedayo; Ayobami Eluwole; Fasika Tedla; Arye Kremer; Muhammad Khan; Nicole Mastrogiovanni; Carl Rosenberg; Paul Dreizen; John La Rosa; Louis Salciccioli; Mohamed Boutjdir; Mary Ann Banerji; Clinton Brown; Jason Lazar; Moro Salifu; Ahmed Bakillah
Journal:  Biomedicines       Date:  2022-07-28

Review 6.  Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo.

Authors:  Emily C Reddy; Margaret L Rand
Journal:  Front Cardiovasc Med       Date:  2020-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.